Tags

Type your tag names separated by a space and hit enter

Penetration of intravenous and oral ciprofloxacin into sterile and empyemic human pleural fluid.
Ann Pharmacother 1994; 28(3):313-5AP

Abstract

OBJECTIVE

To compare the penetration of oral and intravenously administered ciprofloxacin into infected (empyemic) and noninfected (sterile) human pleural fluid.

DESIGN

Eleven men and 5 women (aged 29-76) were consecutively selected from adult patients referred to the respiratory unit for pleural effusion. In this open-label, prospective trial, 13 patients with sterile pleural effusions were nonrandomly assigned to receive either ciprofloxacin 200 mg (single intravenous dose), 750 mg (single oral dose), or 750 mg (two oral doses per day for 3 days); 3 patients with infected pleural effusions received 750 mg oral doses for 10 days. Simultaneous pleural fluid and venous blood specimens were drawn over 5 hours after single dose or when steady-state was attained, and ciprofloxacin concentrations were measured by HPLC.

RESULTS

Pleural fluid concentrations of ciprofloxacin equaled plasma concentrations 1.5 hours after 200 mg was given intravenously and the pleural/plasma ratio remained > or = 0.9 for 4 hours. After a single 750-mg oral dose, pleural ciprofloxacin concentrations rose from 0 to 1.4 micrograms/mL over 5 hours with the highest pleural fluid/plasma ratio (0.7) at 5 hours. Average steady-state ciprofloxacin concentrations in sterile pleural fluid after 750 mg administered twice daily for 3 days, ranged between 1.1 and 1.8 micrograms/mL with ratios between 0.3 and 0.9 over 4 hours. In empyemic pleural fluid at the same dosage, average steady-state ciprofloxacin concentrations ranged between 1.9 and 3.4 micrograms/mL with ratios between 1.0 and 2.0 over 5 hours.

CONCLUSIONS

Oral ciprofloxacin penetrates into sterile and empyemic pleural fluid with concentrations 30-90 percent and 100-200 percent of plasma concentrations, respectively.

Authors+Show Affiliations

Division of Pulmonary and Critical Care Medicine, College of Medicine, Medical University of South Carolina, Charleston.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8193415

Citation

Joseph, J, et al. "Penetration of Intravenous and Oral Ciprofloxacin Into Sterile and Empyemic Human Pleural Fluid." The Annals of Pharmacotherapy, vol. 28, no. 3, 1994, pp. 313-5.
Joseph J, Vaughan LM, Basran GS. Penetration of intravenous and oral ciprofloxacin into sterile and empyemic human pleural fluid. Ann Pharmacother. 1994;28(3):313-5.
Joseph, J., Vaughan, L. M., & Basran, G. S. (1994). Penetration of intravenous and oral ciprofloxacin into sterile and empyemic human pleural fluid. The Annals of Pharmacotherapy, 28(3), pp. 313-5.
Joseph J, Vaughan LM, Basran GS. Penetration of Intravenous and Oral Ciprofloxacin Into Sterile and Empyemic Human Pleural Fluid. Ann Pharmacother. 1994;28(3):313-5. PubMed PMID: 8193415.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Penetration of intravenous and oral ciprofloxacin into sterile and empyemic human pleural fluid. AU - Joseph,J, AU - Vaughan,L M, AU - Basran,G S, PY - 1994/3/1/pubmed PY - 1994/3/1/medline PY - 1994/3/1/entrez SP - 313 EP - 5 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 28 IS - 3 N2 - OBJECTIVE: To compare the penetration of oral and intravenously administered ciprofloxacin into infected (empyemic) and noninfected (sterile) human pleural fluid. DESIGN: Eleven men and 5 women (aged 29-76) were consecutively selected from adult patients referred to the respiratory unit for pleural effusion. In this open-label, prospective trial, 13 patients with sterile pleural effusions were nonrandomly assigned to receive either ciprofloxacin 200 mg (single intravenous dose), 750 mg (single oral dose), or 750 mg (two oral doses per day for 3 days); 3 patients with infected pleural effusions received 750 mg oral doses for 10 days. Simultaneous pleural fluid and venous blood specimens were drawn over 5 hours after single dose or when steady-state was attained, and ciprofloxacin concentrations were measured by HPLC. RESULTS: Pleural fluid concentrations of ciprofloxacin equaled plasma concentrations 1.5 hours after 200 mg was given intravenously and the pleural/plasma ratio remained > or = 0.9 for 4 hours. After a single 750-mg oral dose, pleural ciprofloxacin concentrations rose from 0 to 1.4 micrograms/mL over 5 hours with the highest pleural fluid/plasma ratio (0.7) at 5 hours. Average steady-state ciprofloxacin concentrations in sterile pleural fluid after 750 mg administered twice daily for 3 days, ranged between 1.1 and 1.8 micrograms/mL with ratios between 0.3 and 0.9 over 4 hours. In empyemic pleural fluid at the same dosage, average steady-state ciprofloxacin concentrations ranged between 1.9 and 3.4 micrograms/mL with ratios between 1.0 and 2.0 over 5 hours. CONCLUSIONS: Oral ciprofloxacin penetrates into sterile and empyemic pleural fluid with concentrations 30-90 percent and 100-200 percent of plasma concentrations, respectively. SN - 1060-0280 UR - https://www.unboundmedicine.com/medline/citation/8193415/Penetration_of_intravenous_and_oral_ciprofloxacin_into_sterile_and_empyemic_human_pleural_fluid_ L2 - http://journals.sagepub.com/doi/full/10.1177/106002809402800302?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -